Chemical apparatus and process disinfecting – deodorizing – preser – Blood treating device for transfusible blood
Reexamination Certificate
2000-02-25
2003-07-08
Sykes, Angela D. (Department: 3762)
Chemical apparatus and process disinfecting, deodorizing, preser
Blood treating device for transfusible blood
C604S005040, C604S006090, C210S650000, C210S257100, C210S258000, C210S929000
Reexamination Certificate
active
06589482
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to systems and methods for processing blood, e.g., for filtration, pheresis, or other diagnostic or therapeutic purposes.
BACKGROUND OF THE INVENTION
There are many types of continuous and intermittent blood processing systems, each providing different therapeutic effects and demanding different processing criteria.
For example, hemofiltration emulates normal kidney activities for an individual whose renal function is impaired or lacking. During hemofiltration, blood from the individual is conveyed in an extracorporeal path along a semipermeable membrane, across which a pressure difference (called transmembrane pressure) exists. The pores of the membrane have a molecular weight cut-off that can thereby pass liquid and uremic toxins carried in blood. However, the membrane pores can not pass formed cellular blood elements and plasma proteins. These components are retained and returned to the individual with the toxin-depleted blood. Membranes indicated for hemofiltration are commercially available and can be acquired from, e.g., Asahi Medical Co. (Oita, Japan).
After hemofiltration, fresh physiologic fluid is supplied to toxin-depleted blood. This fluid, called replacement fluid, is buffered either with bicarbonate, lactate, or acetate. The replacement fluid restores, at least partially, a normal physiologic fluid and electrolytic balance to the blood. Usually, an ultrafiltration function is also performed during hemofiltration, by which liquid is replaced in an amount slightly less than that removed. Ultrafiltration decreases the overall fluid level of the individual, which typically increases, in the absence of ultrafiltration, due to normal fluid intake between treatment sessions.
Following hemofiltration, fluid balancing, and ultrafiltration, the blood is returned to the individual.
SUMMARY OF THE INVENTION
The invention provides systems and methods for carrying out hemofiltration. The systems and methods establish an extracorporeal fluid circuit that communicates with hemofilter. The circuit defines within a flexible panel a flow channel that is free of an air interface. The flexible panel includes an in-line sensor region through which fluid pressure in the flow channel can be measured by an external sensor. The systems and methods enable sensing fluid pressure through the in-line sensor region using the external sensor.
The flow channel can convey, e.g., waste from the hemofilter or replacement fluid for return to the individual.
In one embodiment, the systems and methods pump fluid in the flow channel by externally applying peristaltic pressure to the flexible panel. The systems and methods can sense fluid pressure either downstream of where peristaltic pressure is applied or upstream of where peristaltic pressure is applied.
In one embodiment, the systems and methods occlude the flow channel by externally applying force to the flexible panel.
Other features and advantages of the inventions are set forth in the following specification and attached drawings.
REFERENCES:
patent: 3709222 (1973-01-01), DeVries
patent: 3774762 (1973-11-01), Lichtenstein
patent: 3912455 (1975-10-01), Lichtenstein
patent: 4069968 (1978-01-01), Herman
patent: 4127481 (1978-11-01), Malchesky et al.
patent: 4370983 (1983-02-01), Lichtenstein
patent: 4379452 (1983-04-01), DeVries
patent: 4468329 (1984-08-01), Shaldon et al.
patent: 4479760 (1984-10-01), Bilstad et al.
patent: 4479761 (1984-10-01), Bilstad et al.
patent: 4479762 (1984-10-01), Bilstad et al.
patent: 4514295 (1985-04-01), Mathieu et al.
patent: 4526515 (1985-07-01), DeVries
patent: 4537561 (1985-08-01), Xanthopoulos
patent: 4610781 (1986-09-01), Bilstad et al.
patent: 4692138 (1987-09-01), Troutner et al.
patent: 4702829 (1987-10-01), Polaschegg et al.
patent: 4711715 (1987-12-01), Polaschegg
patent: 4713171 (1987-12-01), Polaschegg
patent: 4737140 (1988-04-01), Lee et al.
patent: 4892518 (1990-01-01), Cupp et al.
patent: 4894150 (1990-01-01), Schurek et al.
patent: 4923598 (1990-05-01), Schal
patent: 4997570 (1991-03-01), Polaschegg
patent: 5041098 (1991-08-01), Loiterman et al.
patent: 5125891 (1992-06-01), Hossain et al.
patent: 5204681 (1993-04-01), Greene
patent: 5211849 (1993-05-01), Kitaevich et al.
patent: 5230702 (1993-07-01), Lindsay et al.
patent: 5291205 (1994-03-01), Greene
patent: 5330448 (1994-07-01), Chu
patent: 5344568 (1994-09-01), Kitaevich et al.
patent: 5350357 (1994-09-01), Kamen et al.
patent: 5441636 (1995-08-01), Chevallet et al.
patent: 5462416 (1995-10-01), Dennehey et al.
patent: 5484397 (1996-01-01), Twardowski
patent: 5522998 (1996-06-01), Polaschegg
patent: 5536412 (1996-07-01), Ash
patent: 5581257 (1996-12-01), Greene et al.
patent: 5614677 (1997-03-01), Wamsiedler et al.
patent: 5616305 (1997-04-01), Mathieu
patent: 5679245 (1997-10-01), Manica
patent: 5730713 (1998-03-01), Okarma et al.
patent: 5762805 (1998-06-01), Truitt et al.
patent: 5776345 (1998-07-01), Truitt et al.
patent: 5836908 (1998-11-01), Beden et al.
patent: 5846419 (1998-12-01), Nederlof
patent: 5858238 (1999-01-01), McRea et al.
patent: 5871694 (1999-02-01), Beden et al.
patent: 5902336 (1999-05-01), Mishkin
patent: 5910252 (1999-06-01), Truitt et al.
patent: 5919369 (1999-07-01), Ash
patent: 5923001 (1999-07-01), Morris et al.
patent: 5944709 (1999-08-01), Barney et al.
patent: 6022335 (2000-02-01), Ramadan
patent: 2684879 (1993-06-01), None
patent: 98/30258 (1988-07-01), None
patent: 98/35710 (1998-08-01), None
patent: 98/52628 (1998-11-01), None
patent: 99/42150 (1999-08-01), None
patent: 00/02603 (2000-01-01), None
Baldamus et al, Outcome of Long Term Hemofiltration, International Society of Nephrology, Dec. 28, 1994, pp. S-41—s46.
Quellhorst et al, Postdilution Hemofiltration is Rational and Preferable, Proc. Dialysis Transplant Forum, 1979 pp. 54-58.
Schaefer et al., Chronic Hemofiltration A Critical Evaluation of a New Method for the Treatment of Blood, Artificial Organs, vol. 2, No. 4, pp. 386-394.
Quellhorst et al, Long-Term Morbidity: Hemofiltration vs. Hemodialysis, Dialysis Membranes: Structures and Predictions Contrib Nephrol. Basel, Karger, 1995, vol. 13, pp. 110-119.
Collins et al, Clinical Comparison of Hemodialysis and Hemofiltration, Kidney Int Suppl Dec. 1985; 17: S18-22.
Manns et al, The acu-men: A new device for continuous renal replacement therapy in acute renal failure, Kidney International, vol. 54, 1998, pp. 268-274.
Prisma System Operator's Manual Feb. 1997, Gambro Healthcare.
Diapact CRRT Operating Manual Version 2.2—Mar. 1998, M. Braun Melsungen AG.
Weiss et al, four years' experience of long-term hemofiltration in a Swedish Center; Scand J Urol Nephrol 1989; 23(3):223-9.
Brugger James M
Burbank Jeffrey H.
Treu Dennis M.
Bianco Patricia
NxStage Medical Inc.
Proskauer Rose LLP
Sykes Angela D.
LandOfFree
Extracorporeal circuits for performing hemofiltration... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Extracorporeal circuits for performing hemofiltration..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Extracorporeal circuits for performing hemofiltration... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3043310